证券代码：603321 证券简称：梅轮电梯 公告编号：2025-034 浙江梅轮电梯股份有限公司 第四届监事会第十六次会议决议公告 （五）本次会议由公司监事会主席朱虹女士主持，公司部分董事及高级管理人员列 席了会议。 二、监事会会议审议情况 资金的议案》 公司拟使用募集资金置换预先已投入募集资金投资项目的自筹资金的金额为人民 币 7526.68 万元，使用募集资金置换已支付发行费用的自筹资金的金额为人民币 185.85 万元，合计人民币 7712.53 万元。公司本次募集资金置换时间距离募集资金到账时间不 超过 6 个月，符合相关法规的要求。 具体内容详见公司于同日在指定信息披露媒体披露的《浙江梅轮电梯股份有限公司 关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告》（公告 编号：2025-035）。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 （一）浙江梅轮电梯股份有限公司（以下简称"公司"）第四届监事会第十六次会 议（以下简称"本次会议"）的召开符合《公司法》《公司章程》等相关 ...

证券代码：603321 证券简称：梅轮电梯 公告编号：2025-035 浙江梅轮电梯股份有限公司 关于使用募集资金置换预先投入募投项目 二、发行申请文件承诺募集资金投资项目情况 及已支付发行费用的自筹资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 浙江梅轮电梯股份有限公司（以下简称"公司"）拟使用募集资金置换预先 已投入募集资金投资项目的自筹资金的金额为人民币 7526.68 万元，使用募集资金置 换已支付发行费用的自筹资金的金额为人民币 185.85 万元，合计人民币 7712.53 万元， 公司本次募集资金置换时间距离募集资金到账时间不超过 6 个月，符合相关法规的要 求。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意浙江梅轮电梯股份有限公司向特定对象 发行股票注册的批复》（证监许可〔2025〕1405号），公司本次以简易程序向特定对象 发行人民币普通股（A股）股票42,049,469股，每股面值为人民币1.00元，每股发行价 格为人民币5.66元，此次发行募集资金总额为 ...

Summary of Key Points Core Viewpoint The company, Wuhu Berteli Automotive Safety Systems Co., Ltd., is utilizing raised funds to replace pre-invested self-raised funds and paid issuance expenses, following regulatory compliance and internal approvals [1][6][9]. Group 1: Fundraising Overview - The company issued 28,020,000 convertible bonds with a total fundraising amount of RMB 2,802,000,000, resulting in a net amount of RMB 2,789,650,905 after deducting issuance costs of RMB 12,349,094.60 [1][2]. - All raised funds are stored in a special account approved by the board of directors to ensure proper management and usage [2]. Group 2: Fund Allocation and Adjustments - The total planned investment for projects was RMB 336,949.05 million, with the adjusted amount for raised funds being RMB 278,965.09 million [2][3]. - Specific project funding adjustments include: - Electronic Mechanical Brake (EMB) project: adjusted from RMB 50,000.00 to RMB 22,645.00 million - High-strength aluminum alloy casting project: adjusted from RMB 35,000.00 to RMB 31,091.00 million - Working capital: adjusted from RMB 81,953.30 to RMB 80,718.39 million [2][3]. Group 3: Pre-Investment and Issuance Expenses - As of July 29, 2025, the company pre-invested RMB 71,662.13 million of self-raised funds into the projects [3][5]. - The total issuance expenses amounted to RMB 1,234.91 million, with RMB 314.75 million paid from self-raised funds [5][6]. Group 4: Compliance and Approval Process - The board of directors approved the use of raised funds to replace pre-invested self-raised funds and paid issuance expenses, totaling RMB 71,976.88 million [6][8]. - The monitoring committee confirmed that the procedures followed comply with relevant regulations and do not affect the normal progress of the fundraising projects [8][9]. - The sponsor institution verified that the replacement of funds aligns with the implementation plan and adheres to regulatory requirements [9].

Core Viewpoint - The company plans to use its own funds to pay part of the expenses for the "Digital Platform Upgrade Project" and subsequently replace these with raised funds, amounting to no more than 7.05 million yuan [1][4]. Fundraising Basic Situation - The company issued 17,974,320 convertible bonds at a face value of 100 yuan each, raising a total of 1.797 billion yuan, with net proceeds after deducting issuance costs amounting to 1.327 billion yuan [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects is 2.534 billion yuan, with 1.797 billion yuan planned to be funded by the raised funds, and 443.06 million yuan already utilized [2][3]. Reasons for Using Own Funds - The company needs to use its own funds for salary and social insurance payments during the project implementation, as these payments must be processed through the company's basic deposit account [3][4]. Impact on the Company - The use of self-funds followed by replacement with raised funds is expected to enhance the efficiency of fund utilization and overall operational management, ensuring the smooth progress of the investment project [4][5]. Review Procedures and Opinions - The board and supervisory committee approved the proposal to use self-funds for the project, confirming that this does not harm the interests of the company or its shareholders and complies with relevant regulations [5][6].

Core Viewpoint - The company intends to use its own funds to pay for part of the investment project and subsequently replace it with raised funds, which is in compliance with regulatory requirements and aims to enhance the efficiency of fund utilization [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds, with net fundraising amounting to approximately 253.43 million yuan after deducting related expenses [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects, including the Jiangsu Phase II, Hubei Pharmaceutical Sorting and Processing Center, and Hebei Pharmaceutical Warehouse, amounts to 253.43 million yuan, with 179.74 million yuan allocated from the raised funds [2]. Reasons for Using Own Funds - The company faces challenges in using raised funds directly for certain expenses, such as employee salaries and social insurance, which must be paid through the basic deposit account. Therefore, it plans to use up to 7.05 million yuan of its own funds for these payments and later replace them with raised funds [3][4]. Impact on the Company - The use of self-funds for project payments and subsequent replacement with raised funds is expected to improve fund utilization efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of the projects [4][5]. Review Procedures and Opinions - The company's board and supervisory committee have approved the proposal to use self-funds for the investment project, confirming that this action does not harm the interests of the company or its shareholders and complies with relevant regulations [5].

证券代码：002049 证券简称：紫光国微 公告编号：2025-071 债券代码：127038 债券简称：国微转债 紫光国芯微电子股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 紫光国芯微电子股份有限公司监事会 有资金支付募投项目部分款项并以募集资金等额置换的议案》，并发表审核意见 如下： 经审核，监事会认为：公司使用自有资金支付募投项目部分款项并以募集资 金等额置换事项履行了必要的决策程序，制定了相应的操作流程，不会影响募投 项目的正常实施，不存在变相改变募集资金投向和损害股东利益的情形，也不存 在违反《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》等法律、法规、规章及规范性文件的情形。 具体内容详见公司于同日在《中国证券报》及巨潮资讯网 （http://www.cninfo.com.cn）上披露的《关于使用自有资金支付募投项目部分 款项并以募集资金等额置换的公告》。 特此公告。 紫光国芯微电子股份有限公司（以下简称"公司"）第八届监事会第十六次 会议通知于 2025 年 7 月 25 日以 ...

Core Viewpoint - Beijing Yitang Semiconductor Technology Co., Ltd. plans to use raised funds amounting to CNY 2,097,556,497.48 to replace self-raised funds previously invested in fundraising projects and paid issuance expenses, in compliance with relevant regulations and within six months of the funds being received [1][5][7] Summary of Fundraising Situation - The company raised a total of CNY 2,342,867,334.94 through its initial public offering (IPO) of 295,560,000 shares at a price of CNY 8.45 per share, as confirmed by KPMG Huazhen [1][2] - The raised funds are managed in a dedicated account, with a tripartite supervision agreement signed with the sponsor and the bank [1] Summary of Investment Projects - The net amount raised is lower than the initially disclosed amount in the prospectus, leading to adjustments in the investment amounts for the fundraising projects [2] - The adjusted investment amounts for the projects are as follows: - Yitang Semiconductor Integrated Circuit Equipment R&D Manufacturing Service Center: CNY 250,000,000 - Yitang Semiconductor High-end Integrated Circuit Equipment R&D Project: CNY 234,286,730 - Total adjusted investment: CNY 234,286,730 [2] Summary of Self-raised Funds and Replacement Arrangement - The actual investment amount from self-raised funds prior to the IPO was CNY 2,042,867,334.94, which the company plans to replace with the raised funds [4][6] - The total amount for replacing self-raised funds and issuance expenses is CNY 2,097,556,497.48, which includes CNY 54,689,162.54 for issuance expenses [4][5] Review Procedures - The board and supervisory committee approved the proposal to use raised funds for replacement on July 25, 2025, confirming compliance with regulatory requirements [4][6][7] - The supervisory committee and KPMG Huazhen provided opinions supporting the replacement, affirming that it does not affect the normal progress of fundraising projects or harm shareholder interests [6][7]

Summary of Key Points Core Viewpoint - The company, Jiangsu Xiangteng New Materials Co., Ltd., has received approval to use its own funds to pay for part of the fundraising investment projects and will subsequently replace these with equivalent amounts from the raised funds, ensuring compliance with relevant regulations and maintaining project efficiency [1][7]. Group 1: Fundraising Overview - The company issued 17,171,722 shares at a price of RMB 28.93 per share, raising a total of RMB 496.78 million, with a net amount of RMB 464.49 million after deducting underwriting and other fees [1][2]. - The company has established a special account for the raised funds and signed a tripartite supervision agreement with the bank and the sponsor [2]. Group 2: Investment Project Details - The total investment for the projects is RMB 501.76 million, with an actual planned use of raised funds amounting to RMB 442.34 million [3]. Group 3: Reasons for Using Own Funds - The company faced challenges in directly using raised funds for payroll and other expenses due to regulatory requirements, necessitating the use of its own funds initially [4][5]. - Payments for social insurance, housing funds, and taxes must be made through a unified bank account, complicating the use of multiple accounts for raised funds [4]. - The need for foreign currency payments for overseas purchases and customs duties further limited the use of the raised funds account [5]. Group 4: Operational Process for Fund Replacement - The company plans to use its own funds for project payments and will replace these with raised funds within six months, following a defined approval and replacement process [6]. - The financial department will manage the replacement process, ensuring compliance with the established procedures [6]. Group 5: Impact on the Company - The use of own funds for project payments is aligned with regulatory requirements and is expected to enhance fund utilization efficiency without affecting the normal implementation of the projects [6][7]. Group 6: Approval Process - The board of directors and the supervisory board approved the proposal to use own funds for project payments on July 24, 2025, without needing shareholder approval [6]. Group 7: Sponsor's Verification Opinion - The sponsor, Everbright Securities, confirmed that the decision-making process was followed correctly and that the use of own funds for project payments complies with relevant laws and regulations [7].

一、2021 年度向特定对象发行股票募集资金的基本情况 根据中国证券监督管理委员会出具的《关于同意万达信息股份有限公司向 特定对象发行股票注册的批复》（证监许可20221689 号），公司向特定对象 发行人民币普通股股票（A 股）255,607,229 股，面值为每股人民币 1 元，发行 价格为每股人民币 7.74 元，截至 2023 年 1 月 9 日止，公司本次向特定对象发 行股票（以下简称"本次发行"）募集资金总额为人民币 1,978,399,952.46 元， 扣除本次发行费用（不含税）人民币 26,256,654.78 元，募集资金净额为人民币 合伙）对公司本次发行募集资金的到位情况进行了审验，并于 2023 年 1 月 10 日出具了《验资报告》（信会师报字2023第 ZA10006 号）。公司已对本次发 行的募集资金进行专户存储管理，并与专户银行、保荐机构签订了募集资金三 方（四方）监管协议，对本次向特定对象发行股票募集资金进行监管。 二、募集资金投资项目的基本情况 发行募集资金预计不超过 300,000.00 万元（含 300,000.00 万元），扣除发行费 用后，募集资金净额将全部用于以下 ...

Group 1 - The core point of the announcement is the approval by the Supervisory Board of China General Nuclear Power Corporation to use funds raised from convertible bonds to replace self-raised funds already invested in projects and to cover issuance costs [1][2] - The meeting was held on July 14, 2025, and the proposal received unanimous approval with 5 votes in favor and no votes against or abstaining [1] - The Supervisory Board believes that the use of raised funds aligns with the company's development needs and will enhance capital utilization efficiency, complying with relevant regulations from the China Securities Regulatory Commission and Shenzhen Stock Exchange [1]